Patients undergoing CRTcetuximab within the SCOPE-1 trial ( 258 patients from 36 UK centres ) completed generic - , disease - and treatment-specific health-related quality of life ( HRQL ) questionnaires ( EORTC QLQ-C30 , QLQ-OES18 , Dermatology Life-Quality Index ( DLQI ) ) at baseline and at 7 , 13 , 24 , 52 and 104 weeks .